Replies to post #141211 on Biotech Values

[genisi]

Agree on jq's comments that Replagal's clinical data are problematic. I had thought that post approval data from 8 years of use in EU plus Replagal's treatment protocol approved by the FDA for compassionate use on top of GENZ's contamination issue/market shortage altogether, would have satisfied the FDA this time around.
And I wouldn't bet on that batting average :-)